Join Growin Stock Community!

Mesoblast limitedMESO.US Overview

US StockHealthcare
(No presentation for MESO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MESO AI Insights

MESO Overall Performance

MESO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MESO Recent Performance

-8.17%

Mesoblast limited

0.05%

Avg of Sector

-0.31%

S&P500

MESO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MESO Key Information

MESO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MESO Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Price of MESO

MESO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MESO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.17
PB Ratio
3.43
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-231.13%
Net Margin
-386.04%
Revenue Growth (YoY)
395.31%
Profit Growth (YoY)
-187.63%
3-Year Revenue Growth
48.73%
3-Year Profit Growth
269.64%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.17
PB Ratio
3.43
Price-to-FCF
-
Gross Margin
-231.13%
Net Margin
-386.04%
Revenue Growth (YoY)
395.31%
Profit Growth (YoY)
-187.63%
3-Year Revenue Growth
48.73%
3-Year Profit Growth
269.64%

  • When is MESO's latest earnings report released?

    The most recent financial report for Mesoblast limited (MESO) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MESO's short-term business performance and financial health. For the latest updates on MESO's earnings releases, visit this page regularly.

  • How much debt does MESO have?

    As of the end of the reporting period, Mesoblast limited (MESO) had total debt of 135.14M, with a debt ratio of 0.17. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MESO have?

    At the end of the period, Mesoblast limited (MESO) held Total Cash and Cash Equivalents of 129.98M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of MESO?

    Mesoblast limited (MESO)'s Free Cash Flow (FCF) for the period is -15.69M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 51.16% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.